The short version of hexenoyl group fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-30. Anything still debated is marked as such rather than presented as settled.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility | Soluble in water | Consistent with peptide nature |
| Typical storage | 2 to 8 degrees Celsius | Refrigerated, dry, protected from light |
| Common analytical method | Reversed-phase HPLC | Purity and impurity profiling |
| Identity confirmation | Mass spectrometry | Molecular mass verification |
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
The pharmacology of cyproterone acetate (CPA) concerns the pharmacology (pharmacodynamics, pharmacokinetics, and routes of administration) of the steroidal antiandrogen and progestin medication cyproterone acetate. CPA blocks the effects of androgens like testosterone in the body, which it does by preventing them from interacting with their biological target, the androgen receptor (AR), and by reducing their production by the gonads and hence their concentrations in the body. In addition, it has progesterone-like effects by activating the progesterone receptor (PR). By activating the PR, CPA has antigonadotropic effects and can inhibit fertility and suppress sex hormone production in both men and women. CPA can also produce weak and partial cortisol-like effects at very high doses under certain circumstances by activating the glucocorticoid receptor (GR). CPA can be taken by mouth or by injection into muscle. It has near-complete oral bioavailability, is highly and exclusively bound to albumin in terms of plasma protein binding, is metabolized in the liver by hydroxylation and conjugation, has 15β-hydroxycyproterone acetate (15β-OH-CPA) as a single major active metabolite, has a long elimination half-life of about 2 to 4 days regardless of route of administration, and is excreted in feces primarily and to a lesser extent in urine.
1 June – Roy Taylor, singer and bass player. 3 June – Conor O'Brien, 18th Baron Inchiquin, 79, peer. Born in England. 6 June – Teddy McCarthy, 57, hurler and Gaelic footballer (Sarsfields, Glanmire, Cork senior teams, Munster). 8 June – Paul Coghlan, 79, politician, Senator (1997–2020). 11 June – Michael A. Noonan, 82, television writer. 13 June – Christy Dignam, 63, singer (Aslan). 19 June – Jim McCourt, 79, boxer, Olympic bronze medallist (1964). Born in Northern Ireland. 21 June – Ronnie Nolan, 89, footballer (Shamrock Rovers, Bohermians, national team). 24 June – S. M. Cyril, 86, educator. 28 June – Willie Carrick, 70, footballer (Chelmsford City, Luton Town).
== R == Radial glial cell A type of glial cell present during brain development that serves as a scaffold for migrating neurons and acts as a neural progenitor cell. Rasmussen's encephalitis A rare chronic inflammatory neurological disorder that typically affects one hemisphere of the brain, causing seizures, progressive weakness, and cognitive decline. Receptor potential A change in membrane potential in a sensory receptor cell in response to a stimulus. It may trigger action potentials in sensory neurons. Receptor tyrosine kinase (RTK) A class of receptors involved in cell growth and differentiation. In neuroscience, RTKs mediate responses to neurotrophic factors like BDNF and NGF. Reelin A protein involved in regulating neuronal migration and positioning during brain development. Disruption is associated with lissencephaly and schizophrenia. Reflex A rapid, automatic motor response to a stimulus, often mediated by the spinal cord without conscious brain involvement. Refractory period A brief period following an action potential during which a neuron is less excitable or unable to fire another action potential. Relative refractory period The phase during which a neuron can fire another action potential, but only with a stronger-than-normal stimulus. Follows the absolute refractory period. REM sleep (Rapid Eye Movement sleep) A sleep phase characterized by rapid eye movements, vivid dreams, muscle atonia, and heightened brain activity resembling wakefulness.
The Scottish Government reaffirms its wish to see the Gender Recognition Reform (Scotland) Bill enacted. 11 May – Scotland's warmest day of the year so far is recorded by the Met Office, with a temperature of 25.7 °C at Cassley. 13 May – At the High Court in Kilmarnock, Uber driver Kunathilinghan Mohanthas is sentenced to seven years in prison for killing Christopher Hanton, who he left for dead in Glasgow city centre after ordering him out of his car and knocking him over as he performed a three-point turn in August 2023. 14 May – MSPs unanimously approve the Housing Cladding Remediation Bill with 116 votes in favour of the legislation that seeks to address problems with cladding on buildings and avoid a similar incident to the Grenfell Tower fire in Scotland. 15 May – The Scottish Government declares a national housing emergency during a parliamentary debate at Holyrood, citing UK government budget cuts and austerity as the reasons for a shortage in housing. Justice Secretary Angela Constance confirms that the Scottish Government are to seek powers to facilitate the early release of prisoners in order to prevent overcrowding in prisons. The rules would only apply to those serving under four years and would not apply to those convicted of sexual or domestic violence related offences. 18 May – Four police officers are injured and 19 arrests made in Glasgow city centre as fans celebrate after Celtic win the Premiership.
Sources: en.wikipedia.org
Organ on a chip applications: For example organoids can be used to model diseases with cells derived from patients or they can be used to investigate the development of different tissues (for example the nervous system) in humans and other animals. Some of these areas are further elaborated in the sections below:
At the 2015 China Victory Day Parade, Xi announced a reduction of 300,000 troops from the PLA, bringing its size to 2 million troops. Xi described this as a gesture of peace, while analysts have said that the cut was done to reduce costs as well as to modernize the PLA. In November 2015, the Central Leading Group for Military Reform announced extensive reforms in the PLA called Deepening National Defense and Military Reform. In 2016, Xi reduced the number of theater commands of the PLA from seven to five. He also abolished the four autonomous general departments of the PLA, replacing them with 15 agencies directly reporting to the CMC. Two new branches of the PLA were created under his reforms, the Strategic Support Force and the Joint Logistics Support Force. PLA Second Artillery Corps was upgraded to the PLA Rocket Force. In March 2016, the CMC announced the abolishment of paid services by the PLA and the People's Armed Police (PAP) by 2019, meaning activities like military-run hospitals and hotels open to the public. On 21 April 2016, Xi was named commander-in-chief of the country's new CMC Joint Operations Command Center. In 2018, the PAP was placed under the sole control of the CMC; it was previously under the joint command of the CMC and the State Council through the Ministry of Public Security. The PLA went through further extensive reforms in 2024; the Strategic Support Force was dissolved and the Aerospace Force, the Cyberspace Force and the Information Support Force was established as arms of the PLA, joining the Joint Logistics Support Force.
No direct studies have found ethyl carbamate to be acutely toxic to or carcinogenic in humans. However, studies with rats, mice, and hamsters have shown that ethyl carbamate causes cancer when administered orally, injected, or applied to the skin, and the lowest fatal dose in rats, mice, and rabbits was calculated to be 1.2 g/kg at the least. When ethyl carbamate was used medicinally, about 50% of the patients exhibited nausea and vomiting, and long-time use led to gastroenteric hemorrhages. The compound has almost no odor and a cooling, saline, bitter taste. In 2007, the International Agency for Research on Cancer raised ethyl carbamate to a Group 2A carcinogen, "probably carcinogenic to humans". The IARC has stated that ethyl carbamate can be "reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity in experimental animals". In 2006, the Liquor Control Board of Ontario in Canada rejected imported cases of sherry due to excessive levels of ethyl carbamate. Studies in Hong Kong (2009) and Korea (2015) outline the extent of the accumulative exposure to ethyl carbamate in daily life. Fermented foods such as soy sauce, kimchi, soybean paste, breads, rolls, buns, crackers and bean curd, along with wine, sake and plum wine, were found to be the foods with the highest ethyl carbamate levels in traditional Asian diets.
Sources: en.wikipedia.org
Refrigeration between 2 and 8 degrees Celsius is typical, with protection from moisture and light. Dry, sealed containers help maintain stability over the labeled shelf life. Temperature cycling is usually minimized.
Reversed-phase high-performance liquid chromatography is commonly used to separate and quantify the peptide and its impurities. Mass spectrometry is often paired with it to confirm identity. Together they provide a profile of related substances.
Extreme pH values accelerate hydrolytic degradation of the peptide backbone. Buffered solutions in a near-neutral range generally slow this process. Solution age and temperature also affect the rate of breakdown.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.